Adalimumab for the treatment of adults with psoriasis

NICE technology appraisals [TA146] Published date:

Adalimumab is recommended as a possible treatment for adults with plaque psoriasis only if:

  • their condition is severe and
  • their condition has not improved with other treatments such as ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or they have had side effects with these in the past or there is a medical reason why they should not be given these treatments.

Adalimumab treatment should be continued beyond 16 weeks only if the psoriasis has clearly improved within this time.

The severity of a person's psoriasis before and during treatment should be assessed by considering the redness, thickness and scaliness of the plaques, the area of the body involved, and how the condition affects the person's quality of life.

When assessing a person's psoriasis, healthcare professionals should take into account any disabilities or difficulties in communicating, which might mean that standard assessments do not provide accurate information about their condition.

Get involved